GI Innovation is showing strong performance. Expectations are spreading for the full-scale business development following the proof of the pipeline concept.
As of 10:03 AM on the 30th, GI Innovation is trading at 13,620 KRW, up 6.41% from the previous day.
Jae-kyung Park, a researcher at Hana Securities, explained, "GI Innovation had shown poor stock performance due to concerns about fundraising," adding, "The fundraising concerns were resolved through a third-party allotment capital increase worth 20 billion KRW."
He continued, "Clinical trials of the main pipelines are progressing smoothly," and added, "Going forward, attention should be paid to the full-scale business development following the proof of the pipeline concept of GI-301, as well as the presentations of GI-101 and GI-102 at the second half academic conferences (SITC, ASH)."
He introduced, "GI-301 is an allergy pipeline licensed out to Yuhan Corporation with global rights, with GI Innovation holding a 50% stake." Furthermore, he emphasized, "GI-301 has completed Phase 1a clinical trials and is currently conducting two Phase 1b clinical trials targeting mild allergies and urticaria."
Researcher Park analyzed, "It is expected that the results will be finalized within the second half of this year," and "Following the results, full-scale pipeline business development is anticipated."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
